Hyperoxic exposure monitoring in diving: A farewell to the UPTD

The pulmonary oxygen toxicity index

Pulmonary oxygen toxicity (POT) is a major risk in diving while breathing hyperoxic gas and is also considered in clinical hyperbaric oxygen treatment. The POTindex calculated by the power equation K = t² × PO₂^4.57 with the recovery form Ktr = Ke × e ^{- [- 0.42 + 0.384 × (PO}₂⁾_ex^{] × tr} which are based on chemical and physiological principles, have a better prediction power than other suggested approaches. Reduction of vital capacity as well as incidence of POT are well predicted by the POTindex. Both the cumulative pulmonary toxic effect and concomitant recovery were suggested to operate at the lower toxic range of PO₂ used in saturation diving K = t² × PO₂^4.57 × e^{-0.0135 × t}, and further experimental support is supplied. The recovery time constant for the full range of PO₂ is presented. POTindex is suggested to replace the old method of UPTD for safe diving. Many diving clubs and diving institutes already adopted the POTindex.

Pulmonary oxygen toxicity in occupational diving

One of the hazards of occupational diving is pulmonary oxygen toxicity, which can lead to reduced lung diffusion capacity and fibrosis. The current gold standard to determine the ‘safe limits’ for oxygen was developed more than 50 years ago and lacks the accuracy required for occupational specialists. These restrictions may be overcome by new diagnostic methods like exhaled breath analysis, which would allow occupational specialists to accurately monitor pulmonary health in the individual diver, and thus reduce long-term health effects of professional diving.

Analysis of Volatile Organic Compounds in Exhaled Breath Following a COMEX-30 Treatment Table

The COMEX-30 hyperbaric treatment table is used to manage decompression sickness in divers but may result in pulmonary oxygen toxicity (POT). Volatile organic compounds (VOCs) in exhaled breath are early markers of hyperoxic stress that may be linked to POT. The present study assessed whether VOCs following COMEX-30 treatment are early markers of hyperoxic stress and/or POT in ten healthy, nonsmoking volunteers. Because more oxygen is inhaled during COMEX-30 treatment than with other treatment tables, this study hypothesized that VOCs exhaled following COMEX-30 treatment are indicators of POT. Breath samples were collected before and 0.5, 2, and 4 h after COMEX-30 treatment. All subjects were followed-up for signs of POT or other symptoms. Nine compounds were identified, with four (nonanal, decanal, ethyl acetate, and tridecane) increasing 33–500% in intensity from before to after COMEX-30 treatment. Seven subjects reported pulmonary symptoms, five reported out-of-proportion tiredness and transient ear fullness, and four had signs of mild dehydration. All VOCs identified following COMEX-30 treatment have been associated with inflammatory responses or pulmonary diseases, such as asthma or lung cancer. Because most subjects reported transient pulmonary symptoms reflecting early-stage POT, the identified VOCs are likely markers of POT, not just hyperbaric hyperoxic exposure.